In 2012, former European Commission Dalli submitted a proposal to modernize the European rules on clinical trials. The new Clinical Trials Regulation 536/2014 [2] will replace the current Directive and will enter into force on 28 May 2016. The Directive has been criticized for its unnecessary bureaucracy, high costs and lack of regulatory harmonization [3] . One of the improvements concerns the simplification of the authorization procedure of multinational trials. In the near future, multinational trials will target more specific patient populations, such as subgroups identified through genomic information. To include sufficient participants, it may be necessary to include all member states. In the past, EU member states misused the authorization process to introduce additional requirements. Under the new regime, countries will apply one submission procedure, instead of a 'patchwork' of 27 national regulatory frameworks. The same counts for the safety reporting procedures.
Despite several improvements, the Regulation did not change the 'two-tired' assessment procedure in which two distinct bodies are involved (authorization bodies and ethics committee). This artificial separation induces administrative burdens and cumbersome hurdles to conduct research [4] . Instead, an integrated assessment including both ethical and scientific aspects was not incorporated since this is a matter of internal organization of each member state.
The Regulation strengthens the responsibilities of the sponsor in case clinical trials are conducted in a third country, by establishing an EU contact person, and facilitating supervision and control. Moreover, the European Commission is entitled to control whether regulatory systems of third countries comply the Regulation's basic provisions on clinical trials (data submitted in the application dossier). But how effective are those auditssince it is unlikely that the Commission can enforce these inspections outside its jurisdiction! By transferring the conduct of (industry sponsored) clinical trials to emerging economies such as India and Brazil, collaboration by third country authorities will remain voluntary [5] . Without adequate enforcement mechanisms, ensuring the ethical and scientific integrity of clinical research remains doubtful.
Another striking issue of concern is the fact that the Regulation does not govern experimentation that does not involve intervention (so-called 'non-interventional' studies). A 'non-interventional' study is defined as a clinical study rather than a clinical trial, i.e. similar to an ' observational' study [6] . According to the authors, this concept is not clear and may cause confusion.
Conclusion
Although aimed at restoring Europe's competitiveness in clinical research and the development of innovative treatments and medicines, the new Clinical Trials Regulation still lacks some effective remedies to avoid duplication of clinical research and created some uncertainty by excluding certain experiments.
